Expertise in
8
conditions

Dr. Karen Russell

Oncology
Tmh Physician Partners-Cancer & Hematology
1775 One Healing Pl # 2, 
Tallahassee, FL 
Offers Telehealth
Expertise in
8
conditions
Tmh Physician Partners-Cancer & Hematology
1775 One Healing Pl # 2, 
Tallahassee, FL 

Overview

Karen Russell is an Oncologist in Tallahassee, Florida. Dr. Russell is highly rated in 8 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Sickle Cell Disease.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Tallahassee Memorial Healthcare

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Tmh Physician Partners-Cancer & Hematology
1775 One Healing Pl # 2, Tallahassee, FL 32308

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Liposomal irinotecan, FOLFOX regimen
Study Phase: Phase 2
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

4 Total Publications

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Journal: Future oncology (London, England)
Published: September 27, 2023
Similar Doctors
Expertise in
33
conditions
Dr. Tim Broeseker
Oncology
Expertise in
33
conditions
Dr. Tim Broeseker
Oncology

Tmh Physician Partners-Cancer & Hematology

1775 One Healing Pl # 2, 
Tallahassee, FL 
 (2.1 miles away)
850-431-5360
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tim Broeseker is an Oncologist in Tallahassee, Florida. Dr. Broeseker is highly rated in 33 conditions, according to our data. His top areas of expertise are Autoimmune Hemolytic Anemia, Hemochromatosis, ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Carolyn Johnston
Oncology
Expertise in
13
conditions
Dr. Carolyn Johnston
Oncology

Tallahassee Memorial Healthcare Inc.

1775 One Healing Pl, 
Tallahassee, FL 
 (0.1 miles away)
850-431-5360
Languages Spoken:
English
See accepted insurances

Carolyn Johnston is an Oncologist in Tallahassee, Florida. Dr. Johnston is highly rated in 13 conditions, according to our data. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, and Vulvar Cancer.

Expertise in
12
conditions
Dr. Margarett Ellison
Oncology
Expertise in
12
conditions
Dr. Margarett Ellison
Oncology

Office

1963 Village Green Way Ste C, 
Tallahassee, FL 
 (2.1 miles away)
888-496-6621
Languages Spoken:
English
See accepted insurances

Margarett Ellison is an Oncologist in Tallahassee, Florida. Dr. Ellison is highly rated in 12 conditions, according to our data. Her top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Hysterectomy.

Frequently Asked Questions about Dr. Karen Russell

How do I make an appointment with Dr. Karen Russell?

You can book an appointment with Dr. Karen Russell by calling their office at 850-431-5360. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Karen Russell a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Karen Russell is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Karen Russell specialize in?

While Dr. Karen Russell is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Karen Russell participate in research or clinical trials?

Yes. Dr. Karen Russell has published 4 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Karen Russell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Karen Russell accept my insurance?

Dr. Karen Russell accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 850-431-5360 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Russell's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile